News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
歌禮製藥(01672.HK)選定ASC39複方製劑進行臨床開發
歌禮製藥－Ｂ(01672.HK)公布，已選定ASC30_39 FDC，即每日一次口服小分子GLP-1R激動劑ASC30與每日一次口服小分子胰淀素選擇性胰淀素受體激動劑ASC39的固定劑量複方製劑(FDC)，進行臨床開發。公司預計將於今年第三季度向美國食品藥品監督管理局(FDA)遞交ASC30_39 FDC口服片治療肥胖症的新藥臨床試驗申請。(de/d)~阿思...
Reset
Send
The window will close in 5 seconds
歌禮製藥(01672.HK)選定ASC39複方製劑進行臨床開發
Close
Recommend
4
Positive
4
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

歌禮製藥－Ｂ(01672.HK)  +0.170 (+0.956%)    Short selling $2.82M; Ratio 7.656%   公布，已選定ASC30_39 FDC，即每日一次口服小分子GLP-1R激動劑ASC30與每日一次口服小分子胰淀素選擇性胰淀素受體激動劑ASC39的固定劑量複方製劑(FDC)，進行臨床開發。

公司預計將於今年第三季度向美國食品藥品監督管理局(FDA)遞交ASC30_39 FDC口服片治療肥胖症的新藥臨床試驗申請。(de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-10 16:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.